Beth A. Chasen, M.D.
Department of Nuclear Medicine, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Diagnostic & Interventional Imaging, The University of Texas Health Science Center at Houston, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Diagnostic & Interventional Imaging, The University of Texas Health Science Center at Houston, Houston, TX
Research Interests
Currently funded ongoing projects as nuclear medicine co-principal investigator include:
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia
A Multicenter Open Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution, and Anti-Tumor Activity of 177Lu-OPS201 with Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects with Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2
An International Multi-Centre, Open-Label Study to Evaluate Safety,Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor Positive Neuroendocrine Tumors (NETs)
Education & Training
Degree-Granting Education
| 1999 | Baylor College of Medicine, Houston, Texas, US, MD |
| 1994 | Trinity University, San Antonio, Texas, US, Biology, BS |
Postgraduate Training
| 2002-2006 | Clinical Residency, Diagnostic and Interventional Imaging, University of Texas Health Science Center, Houston, Texas |
| 2001-2002 | Clinical Residency, Nuclear Medicine, Baylor College of Medicine, Houston, Texas |
| 1999-2000 | Clinical Residency, Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2008 | Controlled Substance Registration Certificate (DEA) |
| 2008 | Texas Controlled Substances (DPS) |
| 2007 | American Board of Nuclear Medicine |
| 2006 | American Board of Radiology (ABR) |
| 2004 | Texas Medical Board |
Experience & Service
Faculty Academic Appointments
Associate Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2020
Associate Professor, Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Assistant Professor, Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2013
Assistant Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2013
Instructor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2007
Instructor, Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2007
Administrative Appointments/Responsibilities
Patient Safety Quality Officer, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2021
Patient Safety Quality Officer, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2021
Other Professional Positions
Nuclear Medicine Site Director, Educational Programs in Radiation Oncology, Houston, TX, 2018 - Present
Nuclear Medicine Site Director, Educational Programs in Radiation Oncology, Houston, TX, 2018 - Present
SuperUser OneConnect, The University of MD Anderson Cancer Center, Houston, TX, 2015 - Present
SuperUser OneConnect, The University of MD Anderson Cancer Center, Houston, TX, 2015 - Present
Extramural Institutional Committee Activities
Member, The Administrative Leadership Program (ALP), The University of Texas MD Anderson Cancer Center, 2017 - 2018
Vice Chair, Institutional Review Board (IRB) 1, The University of Texas MD Anderson Cancer Center, 2016 - 2025
Member, DI-PET/CT Leadership Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2022
Member, Executive Committee of the Faculty Senate, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, DI Quality Functional Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, DI Functional Clinical Operations Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Nuclear Medicine Peer Review Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, PET/CT QA & Education Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Representative, CCMS Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 2012 - Present
Member, Institutional Review Board (IRB) 1, The University of Texas MD Anderson Cancer Center, 2010 - Present
Department Liaison, Women Faculty Program, The University of Texas MD Anderson Cancer Center, 2010 - 2023
Nuclear Medicine Representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2010 - Present
Honors & Awards
| 2017 | Excellence in Clinical Quality Improvement, MD Anderson President's Recognition for Faculty Excellence |
| 1999 | Montague Lane Award in Clinical Skills, Baylor College of Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2018. 90-Y Radioembolization of liver tumours (primary and metastatic). Conference. International Atomic Energy Agency. Houston, TX, US.
- 2018. 90-Y Radioembolization of liver tumours (primary and metastatic). Conference. International Atomic Energy Agency. Houston, TX, US.
- 2012. Bone Mineral Density: Deconstructing the DEXA. Conference. Curriculum Lecture Series for Baylor College of Medicine and University of Texas Endocrinology Fellows. Houston, TX, US.
- 2012. Bone Mineral Density: Deconstructing the DEXA. Conference. Curriculum Lecture Series for Baylor College of Medicine and University of Texas Endocrinology Fellows. Houston, TX, US.
- 2011. Interesting Cases. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Interesting Cases. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. DEXA Back to the Basics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. DEXA Back to the Basics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. DEXA Back to the Basics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. DEXA Back to the Basics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
National Presentations
- 2020. Issues Related to PRRT Response: Case Examples. Invited. Midwinter Meeting of Society of Nuclear Medicine. Tampa, FL, US.
- 2020. Issues Related to PRRT Response: Case Examples. Invited. Midwinter Meeting of Society of Nuclear Medicine. Tampa, FL, US.
- 2019. Clinical Nuclear Medicine Perspective: Theranostics. Invited. Cancer Theranostics and Molecular Imaging Symposium. Houston, TX, US.
- 2019. Clinical Nuclear Medicine Perspective: Theranostics. Invited. Cancer Theranostics and Molecular Imaging Symposium. Houston, TX, US.
- 2019. Future of PRRT in NET: A magic bullet or hype?. Invited. Expertise Exchange Educational Program in Neuroendocrine Tumor. Houston, TX, US.
- 2019. Future of PRRT in NET: A magic bullet or hype?. Invited. Expertise Exchange Educational Program in Neuroendocrine Tumor. Houston, TX, US.
- 2019. Making Dreams Reality: PRRT in the Clinical Setting. Invited. Annual Meeting of the Southwest Chapter of the Society of Nuclear Medicine and Molecular Imaging. Arling, TX, US.
- 2019. Imaging with Ga68 Dotatate. Invited. Annual Meeting of the Southwest Chapter of the Society of Nuclear Medicine and Molecular Imaging. Arlington, TX, US.
- 2019. Making Dreams Reality: PRRT in the Clinical Setting. Invited. Annual Meeting of the Southwest Chapter of the Society of Nuclear Medicine and Molecular Imaging. Arling, TX, US.
- 2019. Imaging with Ga68 Dotatate. Invited. Annual Meeting of the Southwest Chapter of the Society of Nuclear Medicine and Molecular Imaging. Arlington, TX, US.
- 2012. Thoracic CT and PET/CT: Anatomy and Pathology. Invited. Annual Meeting of Society of Nuclear Medicine. Miami, FL, US.
- 2012. Thoracic CT and PET/CT: Anatomy and Pathology. Invited. Annual Meeting of Society of Nuclear Medicine. Miami, FL, US.
- 2012. Thoracic CT Four Hour Case Review: Midwinter Meeting of Society of Nuclear Medicine. Invited. Thoracic CT Four Hour Case Review: Midwinter Meeting of Society of Nuclear Medicine. Orlando, FL, US.
- 2012. Thoracic CT Four Hour Case Review: Midwinter Meeting of Society of Nuclear Medicine. Invited. Thoracic CT Four Hour Case Review: Midwinter Meeting of Society of Nuclear Medicine. Orlando, FL, US.
- 2011. Thoracic CT and PET/CT: Anatomy and Pathology, Read with the Experts Session. Invited. Annual Meeting of Society of Nuclear Medicine. San Antonio, TX, US.
- 2011. Thoracic CT and PET/CT: Anatomy and Pathology, Read with the Experts Session. Invited. Annual Meeting of Society of Nuclear Medicine. San Antonio, TX, US.
- 2008. PET/CT Variants. Invited. Annual Meeting of Society of Nuclear Medicine. New Orleans, LA, US.
- 2008. PET/CT Variants. Invited. Annual Meeting of Society of Nuclear Medicine. New Orleans, LA, US.
- 2008. Bone Density. Invited. Annual Meeting of Society of Nuclear Medicine. New Orleans, LA, US.
- 2008. Bone Density. Invited. Annual Meeting of Society of Nuclear Medicine. New Orleans, LA, US.
- 2008. Organizing and Streamlining your PET/CT Report. Invited. Savannah-Oncologic Imaging. Savannah, GA, US.
- 2008. Organizing and Streamlining your PET/CT Report. Invited. Savannah-Oncologic Imaging. Savannah, GA, US.
- 2008. PET/CT: Chest and Abdomen. Invited. Savannah-Oncologic Imaging. Savannah, GA, US.
- 2008. PET/CT: Chest and Abdomen. Invited. Savannah-Oncologic Imaging. Savannah, GA, US.
International Presentations
- 2019. 90-Y Radioembolization of liver tumours (primary and metastatic). Invited. Regional Training Course on Targeted Radionuclide Therapy. Houston, US.
- 2019. 90-Y Radioembolization of liver tumours (primary and metastatic). Invited. Regional Training Course on Targeted Radionuclide Therapy. Houston, US.
- 2016. 90-Y Radioembolization of liver tumours (primary and metastatic). Invited. Regional Training Course on Targeted Radionuclide Therapy. Houston, US.
- 2016. 90-Y Radioembolization of liver tumours (primary and metastatic). Invited. Regional Training Course on Targeted Radionuclide Therapy. Houston, US.
Selected Publications
Peer-Reviewed Articles
- Dasari, NV, Wallace, K, Halperin, DM, Maxwell, JE, Kunz, PL, Singh, S, Chasen, B, Yao, JC. Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Network Open 8(6), 2025. e-Pub 2025. PMID: 40553474.
- Gonzalez, F, Ravizzini, G, Santiago, G, Chasen, B, Hussein, A. Comparison of Three Therapeutic Radiopharmaceutical Infusion Methods for Single and Multivial Applications. Journal of nuclear medicine technology 53(3):187-192, 2025. e-Pub 2025. PMID: 40796234.
- Singh, S, Halperin, DM, Myrehaug, S, Herrmann, K, Pavel, M, Kunz, PL, Chasen, B, Tafuto, S, Lastoria, S, Capdevila, J, García-Burillo, A, Oh, DY, Yoo, C, Halfdanarson, TR, Falk, S, Folitar, I, Zhang, Y, Aimone, P, De Herder, WW, Ferone, D. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2). The Lancet 403(10446):2807-2817, 2024. e-Pub 2024. PMID: 38851203.
- Chang, E, Wong, FC, Chasen, B, Erwin, WD, Das, P, Holliday, EB, Koong, A, Ludmir, EB, Minsky, B, Noticewala, SS, Smith, GL, Taniguchi, C, Rodriguez, MJ, Beddar, S, Martin, RM, Niedzielski, JS, Sawakuchi, GO, Schueler, E, Perles, LA, Xiao, L, Szklaruk, J, Park, PC, Dasari, NV, Kaseb, A, Kee, BK, Lee, SS, Overman, MJ, Willis, JA, Wolff, RA, Tzeng, CD, Vauthey, JN, Koay, EJ. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectrum 8(3), 2024. e-Pub 2024. PMID: 38730548.
- Cordero-Hernandez, IS, Ross, AC, Dasari, NV, Halperin, DM, Chasen, B, Yao, JC. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocrine-related cancer 31(4), 2024. e-Pub 2024. PMID: 38329269.
- Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BA, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, participants NET. Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Natl Cancer Inst. e-Pub 2023. PMID: 37255328.
- Habibollahi P, Odisio BC, Gurusamy V, Kuban JD, Avritscher R, Abdelsalam ME, Chasen BA, Murthy R, Mahvash A. Temporary Reversal of Hepatoenteric Collaterals during 90Y Radioembolization Planning and Administration. Curr Oncol 29(12):9582-9592, 2022. e-Pub 2022. PMID: 36547167.
- Habibollahi P, Odisio BC, Gurusamy V, Kuban JD, Avritscher R, Abdelsalam ME, Chasen BA, Murthy R, Mahvash A. Temporary Reversal of Hepatoenteric Collaterals during 90Y Radioembolization Planning and Administration. Curr Oncol 29(12):9582-9592, 2022. e-Pub 2022. PMID: 36547167.
- Strosberg JR, Srirajaskanthan R, El-Haddad G, Wolin EM, Chasen BR, Kulke MH, Bushnell DL, Caplin ME, Baum RP, Hendifar AE, Öberg K, Ruszniewski P, Santoro P, Broberg P, Leeuwenkamp OR, Krenning EP. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE. J Nucl Med 62(12):1712-1718, 2021. e-Pub 2021. PMID: 33771903.
- Johnson JM, Chen MM, Rohren EM, Prabhu S, Chasen BA, Mawlawi O, Liu HL, Gule-Monroe MK. Delayed FDG PET Provides Superior Glioblastoma Conspicuity Compared to Conventional Image Timing. Front Neurol 12:740280, 2021. e-Pub 2021. PMID: 34867723.
- Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen BA, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
- Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen BA, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
- Baiomy A, Jensen CT, Ward JF, Chasen BA, Ravizzini GC. Incidental 18F-Fluciclovine Uptake in a Desmoid Tumor Detected in a Patient Undergoing PET/CT Imaging for Prostate Cancer. Clin Nucl Med 46(4):355-357, 2021. e-Pub 2021. PMID: 33323736.
- Baiomy A, Jensen CT, Ward JF, Chasen BA, Ravizzini GC. Incidental 18F-Fluciclovine Uptake in a Desmoid Tumor Detected in a Patient Undergoing PET/CT Imaging for Prostate Cancer. Clin Nucl Med 46(4):355-357, 2021. e-Pub 2021. PMID: 33323736.
- Strosberg JR, Srirajaskanthan R, El-Haddad G, Wolin EM, Chasen BR, Kulke MH, Bushnell DL, Caplin ME, Baum RP, Hendifar AE, Öberg K, Ruszniewski P, Santoro P, Broberg P, Leeuwenkamp OR, Krenning EP. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE. J Nucl Med. e-Pub 2021. PMID: 33771903.
- Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen BA, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
- Johnson JM, Chen MM, Rohren EM, Prabhu S, Chasen BA, Mawlawi O, Liu HL, Gule-Monroe MK. Delayed FDG PET Provides Superior Glioblastoma Conspicuity Compared to Conventional Image Timing. Front Neurol 12:740280, 2021. e-Pub 2021. PMID: 34867723.
- Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen BA, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
- Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen BA, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. e-Pub 2020. PMID: 33020644.
- Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen BA, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. e-Pub 2020. PMID: 33020644.
- Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen BA, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 7:117-131, 2020. e-Pub 2020. PMID: 32984089.
- Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen BA, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 7:117-131, 2020. e-Pub 2020. PMID: 32984089.
- Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med. e-Pub 2019. PMID: 31849202.
- Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med. e-Pub 2019. PMID: 31849202.
- Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FCL, Chasen BA, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. e-Pub 2019. PMID: 31670288.
- Stewart KI, Chasen BA, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer 125(19):3347-3353, 2019. e-Pub 2019. PMID: 31225906.
- Stewart KI, Chasen BA, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer 125(19):3347-3353, 2019. e-Pub 2019. PMID: 31225906.
- Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FCL, Chasen BA, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. e-Pub 2019. PMID: 31670288.
- Strosberg J, Wolin E, Chasen BA, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E, Group NS. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 36(25):JCO2018785865, 2018. e-Pub 2018. PMID: 29878866.
- Strosberg J, Wolin E, Chasen BA, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E, Group NS. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 36(25):JCO2018785865, 2018. e-Pub 2018. PMID: 29878866.
- Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 6(1):14, 2018. e-Pub 2018. PMID: 29433571.
- Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 6(1):14, 2018. e-Pub 2018. PMID: 29433571.
- Al Feghali KA, Yeboa DN, Chasen BA, Gule MK, Johnson JM, Chung C. The Use of 68Ga-DOTATATE PET/CT in the Non-invasive Diagnosis of Optic Nerve Sheath Meningioma: A Case Report. Front Oncol 8:454, 2018. e-Pub 2018. PMID: 30386741.
- Al Feghali KA, Yeboa DN, Chasen BA, Gule MK, Johnson JM, Chung C. The Use of 68Ga-DOTATATE PET/CT in the Non-invasive Diagnosis of Optic Nerve Sheath Meningioma: A Case Report. Front Oncol 8:454, 2018. e-Pub 2018. PMID: 30386741.
- Lu Y, Chasen BA, Macapinlac HA. Imaging Characteristics of Chemotherapy Related Adult-Onset Still Disease. Clin Nucl Med 42(12):980-982, 2017. e-Pub 2017. PMID: 29076903.
- Lu Y, Chasen BA, Macapinlac HA. Imaging Characteristics of Chemotherapy Related Adult-Onset Still Disease. Clin Nucl Med 42(12):980-982, 2017. e-Pub 2017. PMID: 29076903.
- Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen BA, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, Investigators NT. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376(2):125-135, 2017. e-Pub 2017. PMID: 28076709.
- Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen BA, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, Investigators NT. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376(2):125-135, 2017. e-Pub 2017. PMID: 28076709.
- Chism CB, Somcio R, Chasen BA, Ravizzini GC. Increased 18F-FDG Uptake Associated With Gastric Banding Surgical Mesh on PET/CT. Clin Nucl Med 41(5):410-1, 2016. e-Pub 2016. PMID: 26825203.
- Chism CB, Somcio R, Chasen BA, Ravizzini GC. Increased 18F-FDG Uptake Associated With Gastric Banding Surgical Mesh on PET/CT. Clin Nucl Med 41(5):410-1, 2016. e-Pub 2016. PMID: 26825203.
- Oki Y, Chuang H, Chasen BA, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
- Oki Y, Chuang H, Chasen BA, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
- Smith J, Murthy R, Lahoti A, Odisio B, Avritscher R, Chasen B, Mahvash A. Temporary Balloon Occlusion of the Common Hepatic Artery for Yttrium-90 Glass Microspheres Administration in a Patient with Hepatocellular Cancer and Renal Insufficiency. Case Rep Radiol. e-Pub 2013.
- Smith J, Murthy R, Lahoti A, Odisio B, Avritscher R, Chasen B, Mahvash A. Temporary Balloon Occlusion of the Common Hepatic Artery for Yttrium-90 Glass Microspheres Administration in a Patient with Hepatocellular Cancer and Renal Insufficiency. Case Rep Radiol. e-Pub 2013.
- Costelloe CM, Chuang HH, Chasen BA, Pan T, Fox PS, Bassett RL, Madewell JE. Bone Windows for Distinguishing Malignant from Benign Primary Bone Tumors on FDG PET/CT. J Cancer 9(4(7)):524-30, 2013. e-Pub 2013. PMID: 23983816.
- Costelloe CM, Chuang HH, Chasen BA, Pan T, Fox PS, Bassett RL, Madewell JE. Bone Windows for Distinguishing Malignant from Benign Primary Bone Tumors on FDG PET/CT. J Cancer 9(4(7)):524-30, 2013. e-Pub 2013. PMID: 23983816.
- Mahvash A, Zaer N, Shaw C, Chasen BA, Avritscher R, Murthy R. Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals. J Vasc Interv Radiol 23(2):277-80, 2012. e-Pub 2012. PMID: 22264555.
- Mahvash A, Zaer N, Shaw C, Chasen BA, Avritscher R, Murthy R. Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals. J Vasc Interv Radiol 23(2):277-80, 2012. e-Pub 2012. PMID: 22264555.
- Costelloe CM, Kundra V, Ma J, Chasen BA, Rohren EM, Bassett RL, Madewell JE. Fast dixon whole-body MRI for detecting distant cancer metastasis: A preliminary clinical study. J Magn Reson Imaging 35(2):399-408, 2012. e-Pub 2012. PMID: 21990095.
- Costelloe CM, Kundra V, Ma J, Chasen BA, Rohren EM, Bassett RL, Madewell JE. Fast dixon whole-body MRI for detecting distant cancer metastasis: A preliminary clinical study. J Magn Reson Imaging 35(2):399-408, 2012. e-Pub 2012. PMID: 21990095.
- Haygood TM, Malhotra K, Ng C, Chasen BA, McEnery KW, Chasen M. Migration of central lines from the superior vena cava to the azygous vein. Clin Radiol 67(1):49-54, 2012. e-Pub 2012. PMID: 22070939.
- Haygood TM, Malhotra K, Ng C, Chasen BA, McEnery KW, Chasen M. Migration of central lines from the superior vena cava to the azygous vein. Clin Radiol 67(1):49-54, 2012. e-Pub 2012. PMID: 22070939.
- Hulme KW, Rong J, Chasen BA, Chuang HH, Cody DD, Wong FC, Kappadath SC. A CT Acquisition Technique to Generate Images at Various Dose Levels for Prospective Dose Reduction Studies. AJR Am J Roentgenol 196(2):W144-51, 2011. e-Pub 2011. PMID: 21257855.
- Hulme KW, Rong J, Chasen BA, Chuang HH, Cody DD, Wong FC, Kappadath SC. A CT Acquisition Technique to Generate Images at Various Dose Levels for Prospective Dose Reduction Studies. AJR Am J Roentgenol 196(2):W144-51, 2011. e-Pub 2011. PMID: 21257855.
- Costelloe CM, Murphy WA, Chasen BA. Musculoskeletal Pitfalls in 18F-FDG PET/CT: Pictorial Review. AJR Am J Roentgenol 193((3 Suppl)):WS1-WS13, Quiz S26-30, 2009. e-Pub 2009. PMID: 19696250.
- Costelloe CM, Murphy WA, Chasen BA. Musculoskeletal Pitfalls in 18F-FDG PET/CT: Self-Assessment Module. AJR Am J Roentgenol 193((3 Suppl)):S26-30, 2009. e-Pub 2009. PMID: 19696241.
- Costelloe CM, Murphy WA, Chasen BA. Musculoskeletal Pitfalls in 18F-FDG PET/CT: Pictorial Review. AJR Am J Roentgenol 193((3 Suppl)):WS1-WS13, Quiz S26-30, 2009. e-Pub 2009. PMID: 19696250.
- Costelloe CM, Murphy WA, Chasen BA. Musculoskeletal Pitfalls in 18F-FDG PET/CT: Self-Assessment Module. AJR Am J Roentgenol 193((3 Suppl)):S26-30, 2009. e-Pub 2009. PMID: 19696241.
- Gayed IW, Chang J, Kim EE, Nuñez R, Chasen BA, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol 3(8):858-64, 2008. e-Pub 2008. PMID: 18670303.
- Gayed IW, Chang J, Kim EE, Nuñez R, Chasen BA, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol 3(8):858-64, 2008. e-Pub 2008. PMID: 18670303.
Review Articles
- Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BA, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, participants NET. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst 115(9):1001-1010, 2023. e-Pub 2023. PMID: 37255328.
- Jimenez C, Erwin W, Chasen BA. Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. Cancers (Basel) 11(7), 2019. e-Pub 2019. PMID: 31330766.
- Jimenez C, Erwin W, Chasen BA. Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. Cancers (Basel) 11(7), 2019. e-Pub 2019. PMID: 31330766.
- Rayamajhi SJ, Lee J, Mittal BR, Jessop AC, Chasen BA, Bhosale P. Cross sectional and nuclear medicine imaging of pancreatic insulinomas. Abdom Radiol (NY) 42(2):531-543, 2017. e-Pub 2017. PMID: 27639564.
- Rayamajhi SJ, Lee J, Mittal BR, Jessop AC, Chasen BA, Bhosale P. Cross sectional and nuclear medicine imaging of pancreatic insulinomas. Abdom Radiol (NY) 42(2):531-543, 2017. e-Pub 2017. PMID: 27639564.
Other Articles
- .
- .
Abstracts
- Jackson J, Smith A, Swanston N, Chasen BA, Fitzgerald, Rohren E, Macapinlac HA. Bismuth shielding: A tool to reduce CT dose to female pediatric breast tissue during PET/CT acquisition, while not compromising image data. J Nucl Med, 2008. e-Pub 2008.
- Jackson J, Smith A, Swanston N, Chasen BA, Fitzgerald, Rohren E, Macapinlac HA. Bismuth shielding: A tool to reduce CT dose to female pediatric breast tissue during PET/CT acquisition, while not compromising image data. J Nucl Med, 2008. e-Pub 2008.
Patient Reviews
CV information above last modified July 22, 2026